Jazz Pharmaceuticals - JAZZ Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $173.43
  • Forecasted Upside: 53.72%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$112.82
▲ +0.91 (0.81%)

This chart shows the closing price for JAZZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

Analyst Price Target is $173.43
▲ +53.72% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $173.43, with a high forecast of $230.00 and a low forecast of $113.00. The average price target represents a 53.72% upside from the last price of $112.82.

This chart shows the closing price for JAZZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Jazz Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/9/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/7/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/5/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/3/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/3/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/1/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/30/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/23/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$175.00 ➝ $179.00
10/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$174.00 ➝ $175.00
9/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/19/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$190.00 ➝ $202.00
8/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$188.00 ➝ $166.00
8/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$175.00 ➝ $174.00
8/1/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$140.00 ➝ $120.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/1/2024Needham & Company LLCLower TargetBuy ➝ Buy$208.00 ➝ $205.00
8/1/2024Robert W. BairdLower TargetOutperform ➝ Outperform$160.00 ➝ $154.00
7/12/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $150.00
7/2/2024UBS GroupLower TargetNeutral ➝ Neutral$117.00 ➝ $113.00
6/20/2024Needham & Company LLCLower TargetBuy ➝ Buy$222.00 ➝ $210.00
6/5/2024The Goldman Sachs GroupInitiated CoverageBuy$169.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00
5/3/2024BarclaysLower TargetOverweight ➝ Overweight$230.00 ➝ $200.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$222.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
3/22/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$170.00 ➝ $190.00
3/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
3/20/2024Truist FinancialReiterated RatingBuy ➝ Buy$200.00
3/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$220.00
3/20/2024Piper SandlerBoost TargetOverweight ➝ Overweight$171.00 ➝ $188.00
3/15/2024Stifel NicolausBoost TargetBuy ➝ Buy$225.00 ➝ $230.00
3/14/2024HC WainwrightLower TargetBuy ➝ Buy$204.00 ➝ $200.00
3/1/2024UBS GroupLower TargetNeutral ➝ Neutral$135.00 ➝ $131.00
3/1/2024BarclaysLower TargetOverweight ➝ Overweight$235.00 ➝ $230.00
2/29/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
2/29/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$195.00
2/29/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$180.00 ➝ $170.00
2/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$225.00 ➝ $220.00
1/29/2024BarclaysLower TargetOverweight ➝ Overweight$240.00 ➝ $235.00
1/3/2024Robert W. BairdInitiated CoverageOutperform$160.00
12/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$200.00
11/29/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$225.00
11/27/2023UBS GroupDowngradeBuy ➝ Neutral$170.00 ➝ $135.00
11/9/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$200.00 ➝ $191.00
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$226.00 ➝ $225.00
9/28/2023Raymond JamesInitiated CoverageMarket Perform
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
8/14/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$210.00 ➝ $180.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$204.00
8/10/2023Bank of AmericaBoost TargetBuy ➝ Buy$204.00 ➝ $217.00
8/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$203.00 ➝ $201.00
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$226.00
7/10/2023Cantor FitzgeraldReiterated RatingOverweight
5/11/2023Royal Bank of CanadaLower Target$207.00 ➝ $202.00
5/11/2023Needham & Company LLCBoost Target$205.00 ➝ $212.00
3/6/2023HC WainwrightReiterated RatingBuy$204.00
3/3/2023The Goldman Sachs GroupBoost TargetBuy$190.00 ➝ $212.00
3/2/2023Needham & Company LLCLower TargetBuy$210.00 ➝ $205.00
12/8/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$192.00 ➝ $190.00
11/10/2022The Goldman Sachs GroupBoost TargetNeutral$170.00 ➝ $192.00
11/10/2022Royal Bank of CanadaBoost TargetOutperform$206.00 ➝ $207.00
11/10/2022Needham & Company LLCLower TargetBuy$210.00 ➝ $208.00
9/29/2022The Goldman Sachs GroupBoost TargetNeutral$148.00 ➝ $170.00
9/21/2022The Goldman Sachs GroupLower TargetNeutral$192.00 ➝ $148.00
8/5/2022HC WainwrightLower Target$210.00 ➝ $204.00
8/4/2022BMO Capital MarketsBoost TargetOutperform$185.00 ➝ $188.00
8/4/2022Leerink PartnersBoost TargetOutperform$200.00 ➝ $210.00
8/4/2022UBS GroupLower TargetBuy$194.00 ➝ $191.00
8/4/2022Morgan StanleyBoost TargetEqual Weight$174.00 ➝ $187.00
6/13/2022UBS GroupInitiated CoverageBuy$194.00
5/5/2022CowenBoost Target$200.00 ➝ $225.00
5/5/2022CowenBoost Target$200.00 ➝ $225.00
5/5/2022Piper SandlerLower Target$197.00 ➝ $193.00
4/6/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$202.00 ➝ $196.00
3/3/2022HC WainwrightBoost TargetBuy$210.00 ➝ $215.00
3/2/2022Cantor FitzgeraldReiterated RatingOverweight
3/2/2022Piper SandlerLower TargetOverweight$209.00 ➝ $197.00
3/2/2022Royal Bank of CanadaLower TargetOutperform$216.00 ➝ $214.00
3/2/2022BMO Capital MarketsLower Target$202.00 ➝ $187.00
2/7/2022Needham & Company LLCReiterated RatingBuy$215.00
1/20/2022Truist FinancialBoost Target$180.00 ➝ $200.00
12/20/2021Leerink PartnersLower TargetOutperform$230.00 ➝ $200.00
12/17/2021Needham & Company LLCLower TargetBuy$220.00 ➝ $215.00
11/18/2021The Goldman Sachs GroupInitiated CoverageBuy
10/8/2021Morgan StanleyLower TargetEqual Weight$176.00 ➝ $174.00
10/5/2021CitigroupInitiated CoverageBuy$200.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$220.00
8/16/2021HC WainwrightLower TargetBuy$220.00 ➝ $210.00
7/23/2021Royal Bank of CanadaBoost TargetOutperform$190.00 ➝ $216.00
7/22/2021Leerink PartnersReiterated RatingBuy
7/6/2021Jefferies Financial GroupInitiated CoverageBuy$220.00
6/22/2021BarclaysBoost TargetOverweight$235.00 ➝ $250.00
6/21/2021HC WainwrightBoost TargetBuy$212.00 ➝ $220.00
6/18/2021Leerink PartnersBoost TargetOutperform$210.00 ➝ $230.00
5/24/2021Piper SandlerReiterated RatingBuy$214.00
5/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight
5/17/2021HC WainwrightBoost TargetBuy$207.00 ➝ $212.00
5/9/2021Leerink PartnersReiterated RatingBuy
5/7/2021Jefferies Financial GroupReiterated RatingBuy
4/21/2021Cantor FitzgeraldBoost TargetOverweight$185.00 ➝ $198.00
4/14/2021Stifel NicolausBoost TargetBuy$195.00 ➝ $202.00
4/1/2021Morgan StanleyBoost TargetEqual Weight$162.00 ➝ $176.00
3/15/2021Leerink PartnersReiterated RatingOutperform
3/1/2021UBS GroupBoost TargetBuy$174.00 ➝ $228.00
2/25/2021Leerink PartnersLower TargetOutperform$213.00 ➝ $210.00
2/24/2021CowenBoost TargetOutperform$190.00 ➝ $200.00
2/24/2021Jefferies Financial GroupBoost TargetBuy$209.00 ➝ $214.00
2/24/2021Piper SandlerBoost TargetOverweight$175.00 ➝ $205.00
2/5/2021HC WainwrightBoost TargetBuy$195.00 ➝ $207.00
2/3/2021Piper SandlerUpgradeNeutral ➝ Overweight$150.00 ➝ $175.00
1/29/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$177.00 ➝ $162.00
12/15/2020UBS GroupInitiated CoverageBuy$174.00
11/3/2020Wells Fargo & CompanyBoost TargetOverweight$171.00 ➝ $184.00
11/3/2020Royal Bank of CanadaBoost TargetOutperform$170.00 ➝ $180.00
11/3/2020BarclaysBoost TargetOverweight$225.00 ➝ $233.00
11/3/2020Leerink PartnersBoost TargetOutperform$194.00 ➝ $202.00
11/3/2020HC WainwrightBoost TargetBuy$185.00 ➝ $195.00
10/26/2020BarclaysBoost TargetOverweight$205.00 ➝ $225.00
10/20/2020Truist FinancialBoost Target$157.00 ➝ $175.00
10/9/2020Jefferies Financial GroupBoost TargetBuy$151.00 ➝ $188.00
10/9/2020Leerink PartnersBoost TargetOutperform$164.00 ➝ $182.00
10/9/2020HC WainwrightBoost TargetBuy$175.00 ➝ $185.00
9/14/2020Royal Bank of CanadaBoost Target$160.00 ➝ $170.00
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$175.00
9/14/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$128.00
8/13/2020Wells Fargo & CompanyBoost TargetOverweight$150.00 ➝ $171.00
8/6/2020BarclaysReiterated RatingBuy
8/6/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$177.00
7/30/2020OppenheimerInitiated CoverageOutperform
7/28/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform
7/23/2020HC WainwrightUpgradeNeutral ➝ Buy$145.00 ➝ $166.00
6/23/2020BarclaysBoost TargetOverweight$183.00 ➝ $195.00
6/18/2020Bank of AmericaBoost TargetBuy$165.00 ➝ $167.00
6/1/2020Leerink PartnersBoost TargetOutperform$160.00 ➝ $169.00
5/6/2020SunTrust BanksLower TargetBuy$155.00 ➝ $153.00
5/6/2020OppenheimerReiterated RatingBuy$132.00
5/6/2020Leerink PartnersLower TargetOutperform$169.00 ➝ $160.00
5/6/2020BMO Capital MarketsLower TargetPositive ➝ Outperform$205.00 ➝ $193.00
5/6/2020Piper SandlerLower TargetNeutral$127.00 ➝ $113.00
4/30/2020Wells Fargo & CompanyLower TargetOverweight$189.00 ➝ $162.00
4/30/2020OppenheimerLower TargetOutperform$154.00 ➝ $141.00
4/6/2020Jefferies Financial GroupInitiated CoverageBuy$149.00
4/2/2020Morgan StanleyLower TargetEqual Weight$147.00 ➝ $109.00
3/30/2020Royal Bank of CanadaLower Target$164.00 ➝ $174.00
3/23/2020Bank of AmericaLower TargetBuy$178.00 ➝ $163.00
3/12/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$175.00 ➝ $166.00
2/27/2020SunTrust BanksLower TargetBuy$171.00 ➝ $166.00
2/26/2020OppenheimerLower Target$183.00 ➝ $154.00
2/26/2020Piper SandlerLower Target$142.00 ➝ $129.00
2/26/2020BMO Capital MarketsLower TargetOutperform$208.00 ➝ $205.00
2/26/2020Royal Bank of CanadaReiterated RatingOutperform$164.00
2/26/2020CowenLower TargetOutperform$200.00 ➝ $165.00
2/26/2020JPMorgan Chase & Co.Boost TargetOverweight$173.00 ➝ $183.00
1/31/2020SunTrust BanksReiterated RatingBuy$166.00 ➝ $171.00
1/22/2020Wells Fargo & CompanyBoost TargetOverweight$186.00 ➝ $189.00
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$153.00
12/3/2019Wells Fargo & CompanyBoost TargetOutperform$168.00 ➝ $186.00
12/2/2019BarclaysBoost TargetOverweight$182.00 ➝ $200.00
11/11/2019HC WainwrightReiterated RatingHold$147.00
11/11/2019Evercore ISIReiterated RatingBuy
11/7/2019BarclaysReiterated RatingBuy$182.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 22 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
4/3/2024
  • 18 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/3/2024
  • 21 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/2/2024
  • 21 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/2/2024
  • 18 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/1/2024
  • 17 very positive mentions
  • 21 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
8/31/2024
  • 26 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/30/2024
  • 25 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 25 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $112.82
Low: $110.84
High: $113.28

50 Day Range

MA: $110.86
Low: $105.13
High: $117.28

52 Week Range

Now: $112.82
Low: $99.06
High: $134.48

Volume

162,034 shs

Average Volume

670,121 shs

Market Capitalization

$7.11 billion

P/E Ratio

19.38

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Jazz Pharmaceuticals in the last twelve months: Barclays PLC, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for JAZZ.

What is the current price target for Jazz Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Jazz Pharmaceuticals in the last year. Their average twelve-month price target is $173.43, suggesting a possible upside of 55.0%. Stifel Nicolaus has the highest price target set, predicting JAZZ will reach $230.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $113.00 for Jazz Pharmaceuticals in the next year.
View the latest price targets for JAZZ.

What is the current consensus analyst rating for Jazz Pharmaceuticals?

Jazz Pharmaceuticals currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JAZZ.

What other companies compete with Jazz Pharmaceuticals?

How do I contact Jazz Pharmaceuticals' investor relations team?

Jazz Pharmaceuticals' physical mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company's listed phone number is (531) 634-7800 and its investor relations email address is [email protected]. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. Learn More about contacing Jazz Pharmaceuticals investor relations.